Scientists are increasingly investigating retatrutide, a innovative drug created by Eli Lilly, as a potential step in body reduction . Different than many previous approaches, retatrutide is a dual -action agonist targeting simultaneously GLP-1 and GIP, hormones that influence satiety and glucos